Tyler Cooper
Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer

Nelson K Y Wong
Identifying ER-response genes in low-grade serous ovarian cancer for predictive biomarker discovery

Chanel M. Ghesquiere
Differential pre-clinical efficacy of dual CDK4/6 and MEK inhibition in low-grade serous ovarian carcinoma based on KRAS/NF1 tumor mutational status

John Abou-Hamad
Recurrent malignant states in high-grade serous ovarian cancer

Fiona Kessai
Regulation of MYC during therapy-induced senescence of ovarian cancer cells

Matt Borrelli
SPoRTS: a novel, automated workflow for spatiotemporal analysis of live ovarian cancer spheroids expressing ratiometric fluorescent biosensors

Mandana Bigdeli Kheibari
Harnessing cell fate decisions in response to PARPi in HGSOC cells: a one - two - three punch strategy

Aasiya Remtulla
Characterizing novel crosstalk mechanisms between Cdc42/MRCK and RhoA pathways in ovarian cancer cells

Danielle Olding
The effects of MRCK inhibition on ovarian cancer tumour cell signalling and proliferation

Andrea Rivera
SNORA81 increases ovarian cancer invasive potential by modifying the expression of a subset of tumor repressors and enhancers

Guoxiong Xu
Chemoresistant reversal and prediction of therapeutic responses in ovarian cancer

Farhia Kabeer
High grade serous ovarian cancer (HGSOC): Tracking response to therapies in plasma and at single cell resolution

Karolin Heinze
NGS compartment analysis revealed uniformity within the stroma and type-specific differences in the epithelium of endometriosis-associated and high-grade serous ovarian carcinomas

Sarah Nersesian
Distinct NK cell subsets in HGSC: scRNAseq insights and microenvironmental features

Sara Asif
Employing ILC2s to enhance immunotherapy in ovarian cancer

Morgan Pugh-Toole
Structural and biochemical features influence immune cell migration and reactivity in HGSC: insights from an engineered tumor microenvironment

Molly Udaskin
Establishment of HGSOC-derived organoids for modeling therapeutic response

Zacharie Drouin
Developing a novel ex vivo organotypic model to study mechanisms of ovarian cancer brain metastasis

Sarah Saoudaoui
Molecular characterization of senescence induced by PARPi in preclinical xenograft mouse models of breast and ovarian cancer

Jacob Haagsma
Investigating the role of inflammatory signaling in a precursor model of ovarian high-grade serous carcinoma

Nhung Vuong-Robillard
Menopause induced senescence: a potential driver for ovarian cancer metastasis

Komila Zakirova
Netrin signaling supports spheroid dormancy and metastatic spread in HGSOC

Ryhem Gam
"Innovative Ran GTPase Inhibitors: Pioneering a Novel Therapeutic Approach for Epithelial Ovarian Cancer"

Yuen Yee Leung
"FOLR1 as a potential novel therapeutic target in low-grade serous carcinoma of the ovary or peritoneum "

Resh Carter
The effect of miR-200s on ovarian cancer

Jennifer Davis
Investigating sequential and combined treatments of carboplatin and PARP inhibitors using three-dimensional culture models of advanced high-grade serous ovarian cancer

Tiffany Johnston
Investigating synergistic combinations of MRT68921 and afatinib as a therapeutic strategy in epithelial ovarian cancer

Svetlana Djirackor
Cell state origins of endometriosis-associated malignancies

Yojiro Yamanaka
Rethinking about cancer - what is malignancy?

Ramlogan Sowamber
Histotype distribution shift of ovarian cancers following opportunistic salpingectomy

Rebekah J Kukurudz
Interpretation of ovarian cancer risk and subsequent consideration of risk-reducing salpingo-oophorectomy in Hereditary Breast and Ovarian Cancer and Lynch syndrome

Neha S Katote
Income and education inequalities in ovarian cancer mortality in Canada: 1990–2019

Natasha Lawton-Zandstra
Ovarian cancer stem-like cell differentiation trajectories in single cells

Brynne Stewart
Impact of salpingectomy on ovarian cancer risk perception and cancer-related distress in BRCA mutation carriers

Maryam Echaibi ** DUPLICATE **
Secretory leukocyte protease inhibitor secreted from ovarian cancer cells interacts with CD4 receptors on immune cells: a potential target for a better immune response

Olivia R Piccolo
Exploring how BRCA mutations in ovarian fibroblasts create a niche for cancer growth

Maja Kalaba
Perspectives of Canadians with ovarian cancer (OC) on niraparib: An interim analysis of a qualitative study